6 Biotechnology Stocks to Buy Now

Advertisement

This week, six biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

ArQule, Inc. (ARQL) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. ArQule is a biotechnology company that is engaged in the research and development of cancer therapeutics. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

La Jolla Pharmaceutical Company (LJPC) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

This week, Incyte Corporation (INCY) pushes up from a C to a B rating. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Ambit Biosciences Corp. (AMBI) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Progenics Pharmaceuticals, Inc. (PGNX) improves from a C to a B rating this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Shares of the stock have been changing hands at an unusually rapid pace, four times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

This week, Celladon Corporation’s (CLDN) ratings are up from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/6-biotechnology-stocks-to-buy-now-arql-ljpc-incy/.

©2024 InvestorPlace Media, LLC